Skip to content

Relief From Side Effects: Clinical Use of Electrodes With Direction

Relief From Side Effects: Clinical Use of Electrodes With Direction: a Prospective, Open Label, Clinical Trial for Thalamic Deep Brain Stimulation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03795935
Acronym
RESCUED
Enrollment
6
Registered
2019-01-08
Start date
2018-09-17
Completion date
2019-08-01
Last updated
2019-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Brain Stimulation, Directional Lead, Essential Tremor

Keywords

Deep Brain Stimulation, Directional Lead, Essential Tremor

Brief summary

Deep Brain Stimulation (DBS) uses electrical pulses sent through a lead (insulated wire) to help stop unwanted symptoms in a variety of brain diseases, including the tremor seen in patients with Essential Tremor (ET). The current standard lead allows this stimulation to spread out uniformly in all directions. As these diseases progress, however, the amount of electrical stimulation required to stop the symptom usually increases. This may become problematic because the increased electrical stimulation required for advanced symptoms may spread outside the desired targeted area, and effect other parts of the brain and causing unwanted side effects. A new type of DBS lead has been developed which can steer, or focus, the electrical stimulation in a given direction toward the desired target area and away from areas that would cause side effects. We would like to quantify the benefit seen in patients who have been switched from the traditional lead to this new directional lead.

Detailed description

Patients implanted with a DBS may experience unwanted side effects such as motor contractures, paresthesia, or dysarthria. This occurs when the electrical field of the stimulation spreads out beyond the targeted area. This is especially common in patients whose disease has progressed, and must use increasingly higher currents in order to regain control of their tremor. Unfortunately, because the electrical field affects neurons in a symmetrical sphere around the DBS, it is often impossible to reach the additional desired neuronal elements without simultaneously affecting equidistant brain regions responsible for side effects. For many of our advanced patients, this means choosing between a debilitating tremor or disabling side effects.The directional lead is a FDA and Health Canada approved DBS lead which features radially segmented electrodes which can selectively steer the electrical field in a predefined direction, orthogonal to the lead trajectory. This will allow DBS clinicians to steer current towards desired structural areas, while avoiding locations, which produce negative side effects.

Interventions

OTHERNo side-effect stimulator settings with directional lead

Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.

Sponsors

Boston Scientific Corporation
CollaboratorINDUSTRY
University of British Columbia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Participants must have been implanted with the DBS * Participants must have been diagnosed with Essential Tremor * Participants must experience negative side effects from their DBS which limit control over their tremor * Participants must be able to receive benefit from their stimulator, but at the cost of negative side effects

Exclusion criteria

* All individuals who meet criteria outlined in inclusion criteria may be eligible for this study

Design outcomes

Primary

MeasureTime frameDescription
Tremor ControlAssessed once all tests performed - 1 to 2 months post-operativelyMaximum percentage change in tremor (as measured by the Tremor Rating Scale) without side-effects (comparing DBS on versus off) in each patient using the standard lead compared to the directional lead.

Secondary

MeasureTime frameDescription
Quality of life based on participant's best real life settingAssessed during study visits - The initial assessment will occur during a pre-operative study visit which will be compared post operatively 3 months after outcome 1 has been measuredQuality of life will be based on each participant's subjective opinion using the Short Form 36 (SF36) (a patient-reported survey focusing on health and quality of life) assessment form.
Quality of life based on tremor management participant's best real life settingAssessed during study visits - The initial assessment will occur during a pre-operative study visit which will be compared post operatively 3 months after outcome 1 has been measuredQuality of life will be based on each participant's subjective opinion using the Quality of Life in Essential Tremor Questionare.
Quality of life based on voice handicap with participant's best real life settingAssessed during study visits - The initial assessment will occur during a pre-operative study visit which will be compared post operatively 3 months after outcome 1 has been measuredQuality of life will be based on each participant's subjective opinion using the Vocal handicap Index scale.

Countries

Canada

Contacts

Primary ContactChristopher Honey, DPhil
chris.honey@telus.net6048755894
Backup ContactNatasha Sarai, BSN
natasha.sarai@vch.ca6048754111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026